Cochrane Protocol Outlines Systematic Review of Pharmacological Treatments for Uterine Fibroids

Uterine fibroids are the most common benign gynecological tumors, affecting a significant proportion of pre-menopausal women globally, with prevalence rates as high as 80% in African women by age 50. Clinically apparent in 12-25% of reproductive-age women, fibroids are a major cause of gynecological clinic attendance, leading to symptoms like heavy menstrual bleeding, pelvic pain, and infertility. Current management options range from watchful waiting to surgical interventions like myomectomy or hysterectomy, which carry risks and may not be suitable for all patients, especially those desiring fertility. There is a critical need for a comprehensive, evidence-based evaluation of pharmacological alternatives to guide clinical practice and improve patient outcomes.

This document is a protocol for a Cochrane systematic review, outlining the methodology to evaluate pharmacological treatments for uterine fibroids. The review will include randomized controlled trials (RCTs) and quasi-randomized controlled trials comparing any pharmacological intervention against placebo, no treatment, another pharmacological treatment, or surgery in women of reproductive age with uterine fibroids. Researchers will systematically search major electronic databases, including Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, PsycINFO, and CINAHL, along with trial registries and conference proceedings. Primary outcomes will focus on the benefits (e.g., reduction in fibroid size, symptom relief) and harms (e.g., adverse events) of the interventions. Two independent review authors will screen studies, extract data, and assess the risk of bias using the Cochrane risk of bias tool.

As a protocol for a systematic review, this document outlines the planned methodology and does not present primary findings or numerical results. The review aims to synthesize existing evidence on pharmacological interventions for uterine fibroids, comparing them against placebo, other drugs, or surgery. Once completed, the review will provide evidence-based conclusions on treatment efficacy and safety, addressing a critical gap in current clinical guidance. The full systematic review, upon completion, will include detailed quantitative and qualitative analyses of eligible studies, providing specific data on outcomes such as fibroid size reduction, symptom relief, and adverse events. This comprehensive approach will involve searching multiple databases for relevant randomized controlled trials and quasi-randomized controlled trials, assessing risk of bias, and performing meta-analyses where appropriate. The primary outcomes will focus on the effectiveness of treatments in reducing fibroid volume and associated symptoms like heavy menstrual bleeding and pelvic pain, alongside a thorough evaluation of adverse events and quality of life measures. This structured approach ensures a rigorous and transparent synthesis of the best available evidence.